Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Statera Biopharma, Inc. (STAB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2564+0.0114 (+4.65%)
At close: 04:00PM EDT
0.2660 +0.01 (+3.74%)
After hours: 07:15PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close0.2450
Open0.2400
Bid0.2564 x 2200
Ask0.2660 x 1400
Day's Range0.2378 - 0.2674
52 Week Range0.2000 - 4.6600
Volume1,288,637
Avg. Volume996,880
Market Cap12.825M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7620
Earnings DateMar 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for STAB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Statera Biopharma, Inc.
    Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
    Rating
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • GlobeNewswire

    Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

    FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of Certified Public Accountants, BF Borgers CPA PC as the Company’s independent accountant to audit the balance sheet of the Company as of December 31, 2021, and the related statements of operations, stockholders’

  • GlobeNewswire

    Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

    FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 18, 2022 indicating that, because the Company was delinquent in filing its quarterly report on Form 10-Q on May 15, 2022 for the first qua

  • GlobeNewswire

    Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

    Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disordersFORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company intends to enter into a non-binding term sheet with respect to a strategic partnership with Lay Sciences, Inc. (“Lay Sciences”), a d

Advertisement
Advertisement